Landmark IMPACT study to be published in NEJM

RNS Number : 3186L

GlaxoSmithKline PLC

18 April 2018

 

Issued: 18 April 2018, London UK - LSE Announcement

Landmark IMPACT study to be published in NEJM

GlaxoSmithKline plc (LSE/NYSE: GSK) will today announce at 22:00 BST its IMPACT data.

GSK - a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com. 

GSK enquiries:
UK Media enquiries:	Simon Steel	[phone]	(London)
	David Daley	[phone]	(London)
Analyst/Investor enquiries:	Sarah Elton-Farr	[phone]	(London)
	Tom Curry	+ 1 215 751 5419	(Philadelphia)
	James Dodwell	[phone]	(London)
	Jeff McLaughlin	[phone]	(Philadelphia)

Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2017. Registered in England & Wales: No. 3888792 Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS

 

END

 

 

MSCKVLBFVZFXBBF